Skip to content

Interest Income at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
$10M-9.1%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$6M-14.3%
Prime Medicine logo
Prime MedicinePRME
$1.02M-13.6%
Wave Life Sciences logo
Wave Life SciencesWVE
$5.29M+84.0%
Perspective Therapeutics logo
Perspective TherapeuticsCATX
$2.2M-7.8%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$2.57M+15.2%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M-62.2%
Net income-$3.9M-48.3%
EPS (diluted)-$0.19

Balance sheet

See full
Cash & equivalents$52.5M+32.3%
Total debt$230.4K+2,692%
Total equity$135.4M+153%
Total assets$138.0M+150%

Cash flow

See full
Operating cash flow-$3.5M+38.7%

Valuation

See full
Market cap$587.04M+192%
Enterprise value$534.72M+232%

Returns & leverage

See full
Return on equity-15.9%-6.6pp
Debt / equity0.0×
Current ratio56×

Where this comes from

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monopar Therapeutics's interest income?
Monopar Therapeutics (MNPR) reported interest income of $1.33M in Q1 2026.
How has Monopar Therapeutics's interest income changed year-over-year?
Monopar Therapeutics's interest income increased by 123.2% year-over-year, from $596.85K to $1.33M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.